to study search History

Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial

Organizational Data

DRKS-ID:
DRKS00018985
Recruitment Status:
Recruiting ongoing
Date of registration in DRKS:
2019-12-09
Last update in DRKS:
2023-07-04
Registration type:
Prospective

Acronym/abbreviation of the study

TRACE

URL of the study

https://www.trace-study.de/trace

Brief summary in lay language

No Entry

Brief summary in scientific language

For a growing number of patients suffering from various conditions as, e.g., haematological malignancies or diverse genetic disorders, haematopoietic stem cell transplantation (HSCT) or bone marrow transplantation offer the only possible curative options. However, HSCT is associated with three major risks: graft rejection, graft-versus-host disease (GvHD) and opportunistic, mostly viral, infections or reactivations resulting from delayed immune reconstitution. Delayed immune reconstitution, however, often is the direct result of the severe pre-transplantation conditioning treatment and T-cell depletion of the transplant necessary to fight the risks of graft rejection and GvHD. Therefore, the risk for life-threatening opportunistic, mostly viral, infections is increased in post-transplantation patients. The most common infections after HSCT are Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Adenovirus (AdV). The standard treatment approach for viral infections/reactivations is chemotherapy which shows limited efficacy and does not restore immunity. Therefore, effective new treatment options are required for this condition. Previous investigations have shown that sufficient T-cell immunity is essential for the control and prevention of viral reactivations and newly occurring infections after HSCT. The infusion of T-cells is therefore a promising new approach to treat immune-comprised patients. However, infusion with unselected T cells is associated with an increased risk for GvHD due to the high content of alloreactive T cells. A very promising approach to minimize this problem is to remove alloreactive T cells and enrich, isolate and purify virus-specific T cells. This approach has been studied for nearly two decades and the data published up to date indicate that virus-specific T-cell responses after adoptive T-cell transfer protect against virus-related complications post HSCT and restore T-cell immunity, in particular for AdV-, CMV- and EBV-infections. Despite these promising results, virus-specific T-cell transfer is not yet translated into daily clinical practice due to the lack of prospective clinical trials confirming the efficacy of this treatment approach. The overall goal of this phase III, double-blind placebo-controlled study is to confirm efficacy of multivirus-specific T cells to bring this treatment method in clinical routine. Multivirus-specific T cells generated in this study will be directed against all three most common post-HSCT viral infections: AdV, CMV and EBV. Thus, T-cell immunity will be restored to fight and prevent new viral infections. After an initial screening visit, patients eligible to participate in the study will be treated within 28 days after screening. Patients will be randomized in a 2:1 (treatment: placebo) ratio and receive a single infusion with either multivirus-specific T cells or placebo. Patients will be followed up on the day of treatment, 1 day after and 1, 2, 4, 8 and 15 weeks after treatment. Treatment success will be measured by assessing different parameters including symptoms, quality of life, viral load and T-cell immunity in blood samples. Patients eligible to participate in this study are adult and paediatric patients who have received allogeneic stem cell transplantation and suffer from new or reactivated EBV, AdV or CMV infection refractory to standard antiviral treatment for two weeks. Patients from the six European countries Germany, Belgium, Netherlands, UK, France and Italy will be enrolled. In total 130 patients plus 19 screening failures are expected to participate in the study.

Health condition or problem studied

Free text:
MedDRA - C02
Free text:
stem cell transplantation
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
Multivirus (CMV, EBV, AdV-) specific T cells
Arm 2:
Placebo (NaCl)

Endpoints

Primary outcome:
- Percentage of patients with viral clearance (defined as two consecutive negative PCRs) - Percentage of patients with progression between Day 7 and Week 8 after T-cell transfer
Secondary outcome:
- Incidence and severity of newly occurring GvHD =/< grade II until Week 8 and Week 15. - Incidence of newly occurring acute GvHD grade I from Day O to Week 8 and Week 15. - Incidence of chronic GvHD from Day 7 to Week 8 and to Week 15 after IMP transfer - Time to newly occurring acute and chronic GvHD. - Acute toxicity: maximum toxicity on the day of IMP transfer evaluated by measuring vital signs prior to and at different times after the IMP transfer and monitoring of specific adverse events (chills, nausea, vomiting, diarrhoea, abdominal pain, allergic reactions, respiratory dysfunction or headache from 1 hour prior to T-cell transfer to 4 hours post infusion). - Change in viral load of underlying viral infection as assessed by quantitative PCR analysis of peripheral blood; samples taken weekly from Day 7 to Week 8 after IMP transfer as compared to samples taken at Day 0. - Time to 1 log change in viral load. - Percentage of patients with ≥1 log decrease in CMV, EBV or AdV viral load at Week 8. - Number of reactivations of the underlying viral infection following initial viral clearance until end of follow-up. - Number of patients with reduction or clearance of clinical symptoms of underlyingviral infection from Day 7 to Week 8 after IMP transfer as compared to Day 0. - Overall survival rate (OS): From Day 0 to end of follow-up. - Number of days requiring antiviral chemotherapy after IMP transfer from Day 7 to Week 8 after T-cell transfer. - Time to last administration of defined antiviral medication or switch to prophylactic treatment from Day 0 to Week 8 after IMP transfer. - Number of new viral reactivations (CMV, AdV or EBV) other than the underlying viral infection per patient as assessed by PCR analysis and clinical symptoms throughout the study. - Number of days hospitalized after IMP transfer from Day 7 to Week 8. - EQ-5D and FACT-BMT for adult patients (≥18 years), and PEDS-QL for paediatric patients (<18 years) at Screening and Week 8. - T-cell phenotyping, samples taken at Screening, Day 0 and each visit from Day 7 to Week 15 after IMP transfer. Analysis of virus-specific T cells: frequencies of in vivo expanded virus-specific T cells in peripheral blood samples taken at Screening, Day 0, Day 7 to Week 15 after T-cell transfer. - Assessment of the number and viability of CD3+ cells and percentage of IFN-gamma+ cells and cellular composition in the IMP. - Drop-out rate at Day 0 and reasons for drop-out. - Number of days from Screening to Day 0 (day of IMP transfer). - Documentation of incidence, severity and type of adverse events from Day 0 to Week 8 and serious adverse events throughout the study. - Physical examination and vital signs from Screening to Week 8; Karnofsky/Lansky index will be assessed at Screening and at Week 8. - Laboratory values for clinical chemistry and haematology from Screening to Week 8. - Documentation of all concomitant medication from Screening to Week 8. - During follow-up Week 15, only antiviral therapy, immunosuppression and SAE-related concomitant medication as well as chemotherapy will be documented. - Non-therapeutic DLI has to be documented as concomitant medication (definition see exclusion criteria). - Treatment with multivirus-specific IMP after Week 8 will also be documented as concomitant medication.

Study Design

Purpose:
Treatment
Allocation:
Randomized controlled study
Control:
  • Placebo
Phase:
III
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
Yes
Assignment:
Other
Sequence generation:
No Entry
Who is blinded:
  • Assessor
  • Caregiver
  • Data analyst
  • Investigator/therapist
  • Patient/subject

Recruitment

Recruitment Status:
Recruiting ongoing
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Belgium
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
Number of study centers:
Multicenter study
Recruitment location(s):
  • University medical center Universitätsklinikum Essen - Pädiatrische Hämatologie-Onkologie Essen
  • University medical center Universitätsklinikum Tübingen, Center for Pediatric Clinical Studies (CPCS) Tübingen
  • University medical center Universitätsklinikum Würzburg - Medizinische Klinik und Poliklinik II & Zentrum Innere Medizin (ZIM) Würzburg
  • University medical center Klinikum rechts der Isar der Technischen Universität - Klinik und Poliklinik für Innere Medizin III München
  • University medical center Universitätsklinikum Leipzig - Medizinische Klinik und Poliklinik I Leipzig
  • University medical center Dr. von Haunersches Kinderspital, Abteilung Hämatologie und Onkologie München
  • University medical center LMU Klinikum - Medizinische Klinik und Poliklinik III München
  • University medical center Universitätsklinikum Düsseldorf - Klinik für Kinder-Onkologie, -Hämatologie und klinische Immunologie Düsseldorf
  • University medical center Charité Berlin (Campus Virchow-Klinikum) - Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie Berlin
  • University medical center Medizinische Hochschule Hannover - Zentrum für Kinderheilkunde und Jugendmedizin Hannover
  • University medical center Klinikum rechts der Isar der Technischen Universität - Kinderklinik Schwabing München
  • University medical center Universitätsklinikum Dresden Dresden
  • University medical center Universitätsklinikum Freiburg - Klinik für Pädiatrische Hämatologie und Onkologie Freiburg
  • University medical center Universitätsklinikum Regensburg - Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation Regensburg
  • University medical center Universitätsklinikum Würzburg - Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation Würzburg

Recruitment period and number of participants

Planned study start date:
2020-02-25
Actual study start date:
2020-02-25
Planned study completion date:
No Entry
Actual Study Completion Date:
No Entry
Target Sample Size:
149
Final Sample Size:
No Entry

Inclusion Criteria

Sex:
All
Minimum Age:
2 Months
Maximum Age:
no maximum age
Additional Inclusion Criteria:
1. Adult or paediatric patients (>2 months of age) after HSCT (no time restrictions apply) suffering from new or reactivated CMV or EBV or AdV infection, refractory to standard antiviral treatment for two weeks (defined as ≤1 log decrease in viral load over two weeks) as confirmed by quantitative blood PCR analysis 2. Original HSCT-donor available with an immune response at least to the virus causing the therapy-refractory (=underlying) infection 3. Written informed consent given (patient or legal representative)

Exclusion Criteria

1. Acute GvHD > grade II or extensive chronic GvHD at time of IMP transfer 2. Treatment with steroids (>1 mg/kg Prednisone equivalent) at Screening 3. Therapeutic donor lymphocyte infusion (DLI) from 4 weeks prior to IMP infusion until 8 weeks post IMP infusion. In case of T-cell depleted HSCT, a prescheduled prophylactic DLI ≤3 x 10e5 T cells/kg BW is not considered an exclusion criteria. 4. Organ dysfunction or failure as determined by Karnofsky (age >16 years) or Lansky (age ≤16 years) score ≤30% 5. Concomitant enrolment in another clinical trial interfering with the endpoints of this study 6. Any medical condition which could compromise participation in the study according to the investigator’s assessment 7. Progression of underlying disease (disease that has led to the indication of HSCT, e.g. leukaemia) that will limit the life expectance below the duration of the study 8. Second line or experimental antiviral treatment other than Ganciclovir/Valganciclovir, Foscarnet, Cidofovir and Rituximab from Screening until 8 weeks after IMP Infusion or prohylactic Treatment other tham Aciclovir or Letermovir throughout the study except approved by sponsor 9. Known HIV infection. In case patients do not have a negative HIV test performed within 6 months before enrolment in the study, HIV negativity has to be confirmed by a negative laboratory test. 10. Female patient who is pregnant or breast-feeding, or adult of reproductive potential not willing to use an effective method of birth control from Screening until the last follow-up visit (FU6, Visit 8) Note: women of childbearing potential must have a negative serum pregnancy test at study entry 11. Known hypersensitivity to iron dextran 12. Patients unwilling or unable to comply with the protocol or unable to give informed consent.

Addresses

Primary Sponsor

Dr. von Haunersches Kinderspital Klinikum der Universität München
Prof Tobias Feuchtinger
Lindwurmstraße 4
80337 Münchenn
Germany
Telephone:
0049 (0) 89 4400 52759
Fax:
0049 (0) 89 4400 54719
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Dr. von Haunersches Kinderspital Klinikum der Universität München
Prof Tobias Feuchtinger
Lindwurmstraße 4
80337 München
Germany
Telephone:
0049 (0) 89 4400 52759
Fax:
0049 (0) 89 4400 54719
Contact per E-Mail
URL:
No Entry

Contact for Public Queries

Dr. von Haunersches Kinderspital Klinikum der Universität München
Prof Tobias Feuchtinger
Lindwurmstraße 4
80337 München
Germany
Telephone:
0049 (0) 89 4400 52759
Fax:
0049 (0) 89 4400 54719
Contact per E-Mail
URL:
No Entry

Principal Investigator

Dr. von Haunersches Kinderspital Klinikum der Universität München
Prof Tobias Feuchtinger
Lindwurmstraße 4
80337 München
Germany
Telephone:
0049 (0) 89 4400 52759
Fax:
0049 (0) 89 4400 54719
Contact per E-Mail
URL:
No Entry

Sources of Monetary or Material Support

Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)

European Commission
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Ethikkommission der Med. Fakultät der LMU
Pettenkoferstraße 8
80336 München
Germany
Telephone:
+49-89-440055191
Fax:
+49-89-440055192
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Date of ethics committee application:
2018-07-30
Ethics committee number:
18-595 fed
Vote of the Ethics Committee:
Approved
Date of the vote:
2018-11-05

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
2018-000853-29
Other secondary IDs:
NL67592.000.19 - central ethics portal Nehterlands CCMO
Other secondary IDs:
6964 - CESP (Central European Submission Portal)
Other secondary IDs:
3788/01 - pei-nr - Paul Ehrlich Institut Vorlage-Nr.
Other secondary IDs:
MTIAECNAT-2019-12 - ANSM (Behörde Frankreich)
Other secondary IDs:
TRACE - sponsor-id - Studienabkürzung ID der Studie von Sponsor
Other secondary IDs:
ClinicalTrials - NCT04832607
Other secondary IDs:
251752 - central ethics portal for UK: IRAS
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
Yes
IPD Sharing Plan:
If the patient agrees, samples and associated information are stored in a biobank at the sponsor's site.

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry